Roche (RHHBY) Expected to Post Earnings on Thursday

Roche (OTCMKTS:RHHBY) is anticipated to announce its resultson Thursday, July 23rd. Analysts expect Roche to announce earnings of $1.58 per share and revenue of $38.1653 billion for the quarter.

Roche Stock Up 2.0%

Shares of Roche stock opened at $51.18 on Thursday. The business has a 50-day moving average of $51.32 and a two-hundred day moving average of $52.69. Roche has a 1 year low of $37.51 and a 1 year high of $60.85. The company has a debt-to-equity ratio of 0.72, a quick ratio of 1.12 and a current ratio of 1.38.

Analyst Upgrades and Downgrades

A number of research analysts have weighed in on the stock. Morgan Stanley raised shares of Roche from an “underweight” rating to an “equal weight” rating and set a $46.00 price target on the stock in a research note on Friday, April 24th. HSBC lowered shares of Roche from a “buy” rating to a “hold” rating in a research note on Monday, July 6th. Finally, Argus upgraded Roche from a “hold” rating to a “buy” rating in a report on Monday, April 6th. Four research analysts have rated the stock with a Buy rating and seven have given a Hold rating to the company. Based on data from MarketBeat.com, the company has a consensus rating of “Hold” and a consensus target price of $51.50.

Institutional Inflows and Outflows

Several large investors have recently bought and sold shares of RHHBY. Hancock Whitney Corp grew its stake in Roche by 4.8% in the third quarter. Hancock Whitney Corp now owns 24,488 shares of the company’s stock valued at $1,024,000 after purchasing an additional 1,116 shares in the last quarter. Verity Asset Management Inc. raised its stake in shares of Roche by 20.9% during the 3rd quarter. Verity Asset Management Inc. now owns 10,990 shares of the company’s stock worth $459,000 after purchasing an additional 1,898 shares in the last quarter. IHT Wealth Management LLC acquired a new stake in shares of Roche in the 4th quarter valued at approximately $400,000. Finally, Atlas Capital Advisors Inc. bought a new position in shares of Roche in the fourth quarter valued at $192,000.

About Roche

Roche Holding AG is a Swiss multinational healthcare company headquartered in Basel, founded in 1896 by Fritz Hoffmann‑La Roche. The company operates primarily through two complementary divisions — Pharmaceuticals and Diagnostics — and is known for integrating drug development with diagnostic capabilities to advance personalized healthcare. In the United States and other international markets, shares trade as American Depositary Receipts under the ticker RHHBY (OTCMKTS:RHHBY).

In pharmaceuticals, Roche focuses on developing and commercializing prescription medicines across therapeutic areas including oncology, immunology, infectious diseases and neuroscience, with a notable emphasis on targeted biologics and personalized therapies.